- Home
- FBYD vs ANVS Comparison
FBYD vs ANVS Comparison
Compare FBYD & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- ANVS
- Stock Information
- Founded
- FBYD 2021
- ANVS 2008
- Country
- FBYD United States
- ANVS United States
- Employees
- FBYD N/A
- ANVS N/A
- Industry
- FBYD
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- FBYD
- ANVS Health Care
- Exchange
- FBYD Nasdaq
- ANVS Nasdaq
- Market Cap
- FBYD 120.8M
- ANVS 92.6M
- IPO Year
- FBYD N/A
- ANVS 2020
- Fundamental
- Price
- FBYD $7.84
- ANVS $5.08
- Analyst Decision
- FBYD
- ANVS Strong Buy
- Analyst Count
- FBYD 0
- ANVS 6
- Target Price
- FBYD N/A
- ANVS $29.67
- AVG Volume (30 Days)
- FBYD 25.7K
- ANVS 330.7K
- Earning Date
- FBYD 02-01-2025
- ANVS 11-08-2024
- Dividend Yield
- FBYD N/A
- ANVS N/A
- EPS Growth
- FBYD N/A
- ANVS N/A
- EPS
- FBYD N/A
- ANVS N/A
- Revenue
- FBYD $7,530,000.00
- ANVS N/A
- Revenue This Year
- FBYD N/A
- ANVS N/A
- Revenue Next Year
- FBYD N/A
- ANVS N/A
- P/E Ratio
- FBYD N/A
- ANVS N/A
- Revenue Growth
- FBYD N/A
- ANVS N/A
- 52 Week Low
- FBYD $5.85
- ANVS $4.21
- 52 Week High
- FBYD $13.25
- ANVS $20.90
- Technical
- Relative Strength Index (RSI)
- FBYD 43.37
- ANVS 40.80
- Support Level
- FBYD $7.57
- ANVS $4.21
- Resistance Level
- FBYD $9.27
- ANVS $5.34
- Average True Range (ATR)
- FBYD 0.89
- ANVS 0.44
- MACD
- FBYD -0.17
- ANVS 0.09
- Stochastic Oscillator
- FBYD 4.75
- ANVS 43.06
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.